Antares Pharma Inc. (ATRS) Downgraded by Zacks Investment Research to “Hold”
Antares Pharma Inc. (NASDAQ:ATRS) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Tuesday.
According to Zacks, “Antares Pharma, Inc. develops, commercializes and markets novel delivery solutions, including needle-free and mini-needle injector systems, gel technologies and transdermal products, which improve both the efficiency of drug therapies and the quality of life for patients. The Company currently distributes its needle-free injector systems for the delivery of insulin and growth hormone in over 20 countries and an estradiol transdermal patch for hormone replacement therapy. “
Separately, Piper Jaffray Cos. restated an “overweight” rating and issued a $2.00 target price (down previously from $3.00) on shares of Antares Pharma in a research note on Saturday, August 13th.
Antares Pharma (NASDAQ:ATRS) traded down 1.11% on Tuesday, reaching $1.78. The company’s stock had a trading volume of 579,111 shares. The stock’s market cap is $276.00 million. Antares Pharma has a 12-month low of $0.67 and a 12-month high of $1.85. The company’s 50 day moving average price is $1.49 and its 200-day moving average price is $1.12.
Antares Pharma (NASDAQ:ATRS) last released its earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported ($0.04) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.04). The company earned $12.20 million during the quarter, compared to analysts’ expectations of $11 million. Antares Pharma had a negative return on equity of 41.06% and a negative net margin of 54.98%. During the same quarter last year, the business posted ($0.01) EPS. On average, equities analysts expect that Antares Pharma will post ($0.15) EPS for the current year.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Janus Capital Management LLC bought a new position in Antares Pharma during the second quarter worth $102,000. Oppenheimer & Co. Inc. raised its position in Antares Pharma by 19.1% in the second quarter. Oppenheimer & Co. Inc. now owns 112,300 shares of the specialty pharmaceutical company’s stock worth $118,000 after buying an additional 18,000 shares during the period. Jane Street Group LLC bought a new position in Antares Pharma during the second quarter worth $133,000. LMR Partners LLP bought a new position in Antares Pharma during the second quarter worth $297,000. Finally, Royce & Associates LP raised its position in Antares Pharma by 318.3% in the first quarter. Royce & Associates LP now owns 406,900 shares of the specialty pharmaceutical company’s stock worth $354,000 after buying an additional 309,616 shares during the period. 36.34% of the stock is owned by institutional investors.
Antares Pharma Company Profile
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.
Receive News & Stock Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related stocks with our FREE daily email newsletter.